Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials - PubMed (original) (raw)
Meta-Analysis
. 2003 Jun 14;361(9374):2017-23.
doi: 10.1016/S0140-6736(03)13637-9.
Affiliations
- PMID: 12814711
- DOI: 10.1016/S0140-6736(03)13637-9
Meta-Analysis
Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials
Deepak P Vivekananthan et al. Lancet. 2003.
Erratum in
- Lancet. 2004 Feb 21;363(9409):662
Abstract
Introduction: Oxidised LDL is thought to play an important part in the pathogenesis of atherosclerosis. Observational studies have associated alpha tocopherol (vitamin E), beta carotene, or both, with reductions in cardiovascular events, but not clinical trials. We did a meta-analysis to assess the effect of these compounds on long-term cardiovascular mortality and morbidity.
Methods: We analysed seven randomised trials of vitamin E treatment and, separately, eight of beta carotene treatment; all trials included 1000 or more patients. The dose range for vitamin E was 50-800 IU, and for beta carotene was 15-50 mg. Follow-up ranged from 1.4 to 12.0 years.
Findings: The vitamin E trials involved a total of 81788 patients and the beta carotene trials 138113 in the all-cause mortality analyses. Vitamin E did not provide benefit in mortality compared with control treatment (11.3 vs 11.1%, odds ratio 1.02 [95% CI 0.98-1.06] p=0.42) or significantly decrease risk of cardiovascular death (6.0 vs 6.0%, p=0.86) or cerebrovascular accident (3.6 vs 3.5%, p=0.31). Beta carotene led to a small but significant increase in all-cause mortality (7.4 vs 7.0%, 1.07 [1.02-1.11] p=0.003) and with a slight increase in cardiovascular death (3.4 vs 3.1%, 1.1 [1.03-1.17] p=0.003). No significant heterogeneity was noted for any analysis.
Interpretation: The lack of a salutary effect was seen consistently for various doses of vitamins in diverse populations. Our results, combined with the lack of mechanistic data for efficacy of vitamin E, do not support the routine use of vitamin E.
Comment in
- Antioxidant vitamins for prevention of cardiovascular disease.
Paolini M, Sapone A, Canistro D, Chieco P, Valgimigli L. Paolini M, et al. Lancet. 2003 Sep 13;362(9387):920; author reply 921. doi: 10.1016/S0140-6736(03)14318-8. Lancet. 2003. PMID: 13678992 No abstract available.
Similar articles
- MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial.
Heart Protection Study Collaborative Group. Heart Protection Study Collaborative Group. Lancet. 2002 Jul 6;360(9326):23-33. doi: 10.1016/S0140-6736(02)09328-5. Lancet. 2002. PMID: 12114037 Clinical Trial. - Antioxidant vitamins and prevention of cardiovascular disease: laboratory, epidemiological and clinical trial data.
Marchioli R. Marchioli R. Pharmacol Res. 1999 Sep;40(3):227-38. doi: 10.1006/phrs.1999.0480. Pharmacol Res. 1999. PMID: 10479466 - The antioxidant vitamins and cardiovascular disease. A critical review of epidemiologic and clinical trial data.
Jha P, Flather M, Lonn E, Farkouh M, Yusuf S. Jha P, et al. Ann Intern Med. 1995 Dec 1;123(11):860-72. doi: 10.7326/0003-4819-123-11-199512010-00009. Ann Intern Med. 1995. PMID: 7486470 Review. - Antioxidant vitamins supplementation and mortality: a randomized trial in head and neck cancer patients.
Bairati I, Meyer F, Jobin E, Gélinas M, Fortin A, Nabid A, Brochet F, Têtu B. Bairati I, et al. Int J Cancer. 2006 Nov 1;119(9):2221-4. doi: 10.1002/ijc.22042. Int J Cancer. 2006. PMID: 16841333 Clinical Trial.
Cited by
- Demystifying Oxidative Stress.
Ghezzi P, Mooradian AD. Ghezzi P, et al. Handb Exp Pharmacol. 2021;264:3-26. doi: 10.1007/164_2020_379. Handb Exp Pharmacol. 2021. PMID: 32767143 - Pharmacogenomic application of the haptoglobin genotype in the treatment of HDL dysfunction.
Schwartz A, Blum S, Asleh R, Pollak M, Kalet-Litman S, Levy AP. Schwartz A, et al. Pharmgenomics Pers Med. 2009;2:1-8. doi: 10.2147/pgpm.s4608. Epub 2009 Feb 27. Pharmgenomics Pers Med. 2009. PMID: 23226030 Free PMC article. - Inhibition of myeloperoxidase oxidant production by N-acetyl lysyltyrosylcysteine amide reduces brain damage in a murine model of stroke.
Yu G, Liang Y, Huang Z, Jones DW, Pritchard KA Jr, Zhang H. Yu G, et al. J Neuroinflammation. 2016 May 24;13(1):119. doi: 10.1186/s12974-016-0583-x. J Neuroinflammation. 2016. PMID: 27220420 Free PMC article. - Nitric oxide mechanisms in the pathogenesis of global risk.
Mason RP. Mason RP. J Clin Hypertens (Greenwich). 2006 Aug;8(8 Suppl 2):31-8; quiz 40. doi: 10.1111/j.1524-6175.2006.05838.x. J Clin Hypertens (Greenwich). 2006. PMID: 16894246 Free PMC article. Review. - Nox1 downregulators: A new class of therapeutics.
Barton M, Meyer MR, Prossnitz ER. Barton M, et al. Steroids. 2019 Dec;152:108494. doi: 10.1016/j.steroids.2019.108494. Epub 2019 Sep 10. Steroids. 2019. PMID: 31518594 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical